CCR4 Inhibitors
1 drugsAbout CCR4
CCR4 (C-C chemokine receptor type 4) is a receptor on immune cells that binds chemokines, triggering intracellular events affecting cell behavior and movement. It directs immune cell trafficking, particularly T cell migration to specific tissues, influencing immune responses.
CCR4 is a drug target due to its role in immune cell migration, but there is currently no genetic evidence available to support its role in disease. Modulation of CCR4 remains a potential therapeutic strategy despite the lack of genetic validation.
POTELIGEO, a biologic drug, is the only FDA-approved drug targeting CCR4, indicated for two conditions and developed by KYOWA KIRIN. This single drug highlights the potential, yet limited, therapeutic focus on CCR4.
Top CCR4 Drugs
KYOWA KIRIN is the only company with an approved drug targeting CCR4.
Low competition suggests potential for market entry, but also indicates higher risk due to limited validation.
CCR4 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets CCR4, using biologic (other) modality.
The absence of small molecule or antibody drugs represents a whitespace opportunity for novel CCR4-targeting modalities.
CCR4 Clinical Trials 18 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on CCR4. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 10 | 6 | 2 | 1 | 75% |
| Phase 2 | 7 | 0 | 0 | 7 | - |
| Phase 4 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
CCR4 Drug Approval Timeline (2018 - 2018)
POTELIGEO was first approved in 2018 and remains the only approved drug.
The lack of recent approvals suggests a potentially saturated market or challenges in developing new CCR4-targeting therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 14 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on CCR4. A trial counts if an approved drug acting on CCR4 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.